Adaptive Biotechnologies Corporation
ADPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $179 | $170 | $185 | $154 |
| % Growth | 5.1% | -8.1% | 20.1% | – |
| Cost of Goods Sold | $72 | $76 | $58 | $49 |
| Gross Profit | $107 | $95 | $127 | $105 |
| % Margin | 59.7% | 55.6% | 68.7% | 68.1% |
| R&D Expenses | $103 | $122 | $142 | $142 |
| G&A Expenses | $73 | $84 | $89 | $75 |
| SG&A Expenses | $158 | $173 | $184 | $170 |
| Sales & Mktg Exp. | $85 | $89 | $96 | $95 |
| Other Operating Expenses | $9 | $27 | $2 | $2 |
| Operating Expenses | $269 | $322 | $328 | $314 |
| Operating Income | -$163 | -$227 | -$200 | -$209 |
| % Margin | -90.8% | -133.3% | -108% | -135.4% |
| Other Income/Exp. Net | $3 | $2 | -$0 | $2 |
| Pre-Tax Income | -$160 | -$225 | -$200 | -$207 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$159 | -$225 | -$200 | -$207 |
| % Margin | -89.1% | -132.3% | -108% | -134.3% |
| EPS | -1.08 | -1.56 | -1 | -1.46 |
| % Growth | 30.8% | -56% | 31.5% | – |
| EPS Diluted | -1.08 | -1.56 | -1 | -1.46 |
| Weighted Avg Shares Out | 147 | 144 | 143 | 140 |
| Weighted Avg Shares Out Dil | 147 | 144 | 143 | 140 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $16 | $4 | $2 |
| Interest Expense | $12 | $14 | $4 | $0 |
| Depreciation & Amortization | $19 | $22 | $21 | $14 |
| EBITDA | -$129 | -$189 | -$175 | -$193 |
| % Margin | -71.9% | -111.2% | -94.6% | -125.3% |